# Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

> **NCT06928272** · PHASE3 · RECRUITING · sponsor: **Douglas D. Fraser** · enrollment: 348 (estimated)

## Conditions studied

- Long COVID

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** Placebo for pirfenidone
- **DRUG:** Upadacitinib
- **DRUG:** Placebo for upadacitinib

## Key facts

- **NCT ID:** NCT06928272
- **Lead sponsor:** Douglas D. Fraser
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06928272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06928272, "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06928272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*